Since current evidence does not suggest that AKI in neurocritical patients should be managed differently from AKI in other critically ill populations, KDIGO-bundle recommendations (i.e., reduce nephrotoxic agents, monitor SCr/UOP, discontinue renin-angiotensin-system blockers, optimize fluid status) are considered appropriate [68]. This evidence concerns the gene REN and acute kidney injury.